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Mutant Desmocollin-2 Causes Arrhythmogenic Right Ventricular
Cardiomyopathy
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Thomas Wichter, Craig T. Basson, Bruce B. Lerman, Sabine Sasse-Klaassen, Ludwig Thierfelder,
Calum A. MacRae, and Brenda Gerull
Arrhythmogenic right ventricular cardiomyopathy (ARVC) is a genetically heterogeneous heart-muscle disorder char-
acterized by progressive ﬁbrofatty replacement of right ventricular myocardium and an increased risk of sudden cardiac
death. Mutations in desmosomal proteins that cause ARVC have been previously described; therefore, we investigated
88 unrelated patients with the disorder for mutations in human desmosomal cadherin desmocollin-2 (DSC2). We iden-
tiﬁed a heterozygous splice-acceptor–site mutation in intron 5 (c.631-2ArG) of the DSC2 gene, which led to the use of
a cryptic splice-acceptor site and the creation of a downstream premature termination codon. Quantitative analysis of
cardiac DSC2 expression in patient specimens revealed a marked reduction in the abundance of the mutant transcript.
Morpholino knockdown in zebraﬁsh embryos revealed a requirement for dsc2 in the establishment of the normal my-
ocardial structure and function, with reduced desmosomal plaque area, loss of the desmosome extracellular electron-
dense midlines, and associated myocardial contractility defects. These data identify DSC2 mutations as a cause of ARVC
in humans and demonstrate that physiologic levels of DSC2 are crucial for normal cardiac desmosome formation, early
cardiac morphogenesis, and cardiac function.
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Arrhythmogenic right ventricular cardiomyopathy/dys-
plasia (ARVC/D [MIM 107970]) is a myocardial disorder
characterized by progressive loss of cardiomyocytes and
ﬁbrofatty replacement.1,2 The disease commonly affects
the right ventricle, but left ventricular involvement can
also arise. ARVC often presents with ventricular arrhyth-
mias originating in the right ventricle and is a major cause
of sudden death in the young.1–3
Familial forms of ARVC exist, although their prevalence
varies widely.4,5 Several genomic loci and six disease genes
have been identiﬁed in autosomal dominant and recessive
forms of ARVC. These genes primarily encodedesmosomal
proteins, but mutations in the cardiac ryanodine receptor
(RYR2) have been described in some families with dis-
tinctive clinical phenotypes, and there are limited data
that perturbed transforming growth-factor b3 (TGFb3) sig-
naling may result in ARVC.6–9 Mutations in plakoglobin
(JUP) and desmoplakin (DSP) genes cause autosomal re-
cessive ARVC in syndromes involving skin and hair, as
well as heart.10,11 More recently, dominant mutations in
DSP have been described, while mutations in plakophilin-
2 (PKP2) have been reported to be responsible for a major
proportion of ARVC cases.12–16 JUP, DSP, and PKP2 are all
components of the desmosomal intercellular junction
complex known to be essential for maintaining tissue
integrity and, increasingly, implicated in cell signaling.
Other major constituents of the desmosomal plaque are
the desmosomal cadherins—desmocollin (DSC) and des-
moglein (DSG). These are type I integral membrane gly-
coproteins that contain four highly conserved extracellular
subdomains (ECs), a more variable extracellular anchor
domain, a single transmembrane domain, an intracellular
anchor domain, and additional cytoplasmatic subdo-
mains. Within the ﬁrst extracellular domain is a highly
conserved cell adhesion–recognition (CAR) sequence
thought important for heterophilic interaction in des-
mosomal cadherin-based adhesion.17–19 In addition to cal-
cium-dependent cell adhesion, these proteins are regula-
tors of tissue morphogenesis and also may participate in
intracellular signaling processes.17–21 Mutations in DSG2
have recently been identiﬁed in ARVC,14,22 so we hypoth-
esized that mutations inDSC2may account for some cases
of the disease. Using a zebraﬁsh model system, we also
have determined a requirement for DSC2 in the emer-
gence of normal myocardial structure and function.
After giving their written informed consent under an
institutional review board–approved protocol, a total of
88 unrelated white patients who were given diagnoses of
ARVC, according to European Society of Cardiology and
International Society and Federation of Cardiology Task
Force criteria,23 and who were without mutations in the
PKP2 gene were screened for mutations in all exons and
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Figure 1. DSC2 mutation c.631-2ArG causes ARVC. A, Partial nucleotide sequence of DSC2 intron 5–exon 6 junction. The genomic
sequence shows a heterozygous ArG transition in the splice-acceptor site position of intron 5. B, Partial nucleotide sequence of cloned
wild-type (WT) and mutant (MUT) transcripts derived from DSC2 cDNA of the mutation carrier (pCR2.1 plasmid) (TOPO-TA cloning
[Invitrogen]). The mutant transcript shows a deletion of the ﬁrst 25 bp of exon 6, which causes a frameshift and a premature stop
codon after 10 novel aa residues (MGILQNFHCP*). C, Schematic view of the splicing mechanism in normal and mutant DSC2. The mutation
c.631-2ArG (arrowhead) affects the splice-acceptor site of intron 5 and activates an alternative cryptic splice site (arrow) in exon 6.
The consequence is a 25-bp deletion that shifts the reading frame and generates a premature stop codon.
ﬂanking intronic sequences of DSC2 and DSG2, by di-
rect bidirectional sequencing of PCR-ampliﬁed genomic
fragments. In one 58-year-old male patient, we identiﬁed
an ArG transition in DSC2 that affects the highly con-
served 3′ splice-acceptor site of intron 5 (c.631-2ArG)
(ﬁg. 1A). This DSC2 variant (GenBank accession number
NM_024422.2) was not present in 500 white control chro-
mosomes. No other mutations were found in DSC2 or
DSG2 in the 88 probands.
Clinical evaluation of the patient with the c.631-2ArG
mutation (table 1) revealed an electrocardiogram (ECG)
with inverted T waves across the precordial leads (V1–V6),
an epsilon wave in lead V1 (ﬁg. 2A), and echocardio-
graphic as well as angiographic evidence of a severely di-
lated, hypokinetic right ventricle with diastolic bulging
and trabecular disarrangement (ﬁg. 2C). Left ventricular
size and function were normal. Ventricular arrhythmias
with left bundle branch block morphology (ﬁg. 2B) were
apparent by age 43 years and led to the implantation of
a cardiac deﬁbrillator and the initiation of antiarrhythmic
medication. The family history was negative for other po-
tentially clinically affected individuals. The father of the
patient died of pneumonia at age 64 years, and the pa-
tient’s mother died of cancer at age 71 years. The clinically
unaffected 61-year-old sister was not available for genetic
analyses.
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Table 1. Clinical Findings of the Patient with the DSC2 Mutation
Metric and Clinical Findings
Task Force
Criteriaa
(Major/Minor)
Twelve-lead ECG:
Epsilon wave in V1 1/0
Inverted T waves in precordial leads (V1–V6) 0/1
Holter monitoring:
Nonsustained left bundle branch block–type tachycardia 0/1
2D echocardiogram/right ventricular angiogram:
Severe dilatation and hypokinesia of the right ventricle, trabecular disarrangement,
diastolic bulging, no left ventricular involvement 1/0
Tissue characteristics of a right ventricular biopsy:
Mild interstitial ﬁbrosis and fatty inﬁltration of myocardium 0/0
Family history:
No additional family members available 0/0
Diagnostic score 2/2
a For the diagnosis of ARVC to be established, the subject must meet two major criteria, one major and
two minor criteria, or four minor criteria in different categories.23
To further investigate the c.631-2ArG mutation, we
performed RT-PCR with exon-linking oligonucleotides
(c607F/c1073R) (table 2) of DSC2 mRNA from both lym-
phocytes and with a cardiac biopsy sample obtained from
the proband. In lymphocytes, in addition to the transcript
of normal size, there was evidence of a shorter DSC2 tran-
script. RT-PCR products were cloned, and sequencing anal-
ysis revealed aberrant splicing of the mutant transcript,
with activation of a cryptic splice-acceptor site in exon 6
and deletion of 25 nt. The mutant transcript encoded a
frameshift resulting in 10 novel aa residues and a pre-
mature termination codon (ﬁg. 1B and 1C). The predicted
truncated DSC2 molecule lacks the highly conserved CAR
sequence of DSC2 thought to be required for heterophilic
adhesive interactions. RT-PCR from cardiac mRNA of the
patient did not reveal evidence of the truncated transcript.
In addition, we performed allele-speciﬁc real-time PCR to
quantify the amounts of mRNA of wild-type and mutant
transcripts in cardiac tissue. We designed allele-speciﬁc
forward primers (c631F/c800R and cMutF/c800R) (table 2)
of DSC2 and performed real-time PCR experiments on in-
dividual RNA samples from the cardiac biopsy of the pa-
tient and control samples, by monitoring the increase of
ﬂuorescence through the binding of SYBR green to double-
stranded DNA (iCycler [Biorad]). mRNA expression data
were normalized to b2-microglobulin and 28S-RNA con-
tent. We found a marked reduction of the mutant DSC2
transcript (3% mRNA abundance), and the specimen of
the patient contained less wild-type DSC2 mRNA (60%)
compared with control myocardium (ﬁg. 3A). These mRNA
expression data were further supported by western-blot
analysis of the cardiac biopsy sample performed with
DSC2 (Progen and gift from W. W. Franke [Heidelberg], 1:
10,000) antibodies. The specimen of the patient contained
less wild-type DSC2 protein than did control myocardium
(ﬁg. 3B).
To explore the in vivo effects of the mutated DSC2 on
cardiac structure and function, we recapitulated the effects
of this splice-site mutation in zebraﬁsh. We ﬁrst cloned
the zebraﬁsh ortholog of human DSC2 by PCR by ho-
mology with public genomic data. The full-length ORF
encodes an 892-aa protein sharing 34% identity with the
human protein, and it contains all the major DSC do-
mains.Whole-mount in situ hybridization throughoutde-
velopment, with use of sense or antisense riboprobe gen-
erated from the full-length clone (GenBank accession
number BX649302) and standard protocols, revealed that
this zebraﬁsh dsc2 was expressed at relatively low levels
in the brain and heart. The most obvious expression in
the heart was seen at 48 h post fertilization (hpf) (ﬁg. 4A–
4C). Cross-sections of the heart conﬁrmed staining in the
atrium, ventricle, and both the inﬂow and outﬂow tracts
(ﬁg. 4D).
Using antisense morpholino oligos, we were able to tar-
get not only the translation start site but also the splice-
acceptor sites for exon 6 and exon 11 of zebraﬁsh dsc2.
Each of the three morpholinos resulted in marked reduc-
tion in the levels of dsc2 mRNA in the morphant embryos
(ﬁg. 4M). Themorpholino phenotypes revealed signiﬁcant
dose-dependent bradycardia, chamber dilatation, and ab-
normal cardiac contractility with progressive pericardial
edema developing by 48 hpf in morphant ﬁsh (ﬁg. 4E–
4H). No abnormalities were evident in embryos injected
with mismatch control morpholino over a broad range of
doses. The mean SD heart rate in control ﬁsh was 136.7
 8.3 beats per min (bpm) ( ) at 22C versus 114.4np 12
 9 bpm ( ) in morphant embryos ( ) (ﬁg. 4L).np 12 P ! .05
Cardiac-chamber size and contractility were measured us-
ing high-speed video microscopy (ﬁg. 4N). Fractional
shortening was reduced from 0.66  0.09 to 0.41  0.07
in control versus morphant embryos, respectively, at 48
hpf ( ). The ventricular-end systolic short-axis di-P ! .05
ameter was increased from 18.1  5.7 mm in control ﬁsh
to 32.2  5.5 mm in morphant ﬁsh (ﬁg. 4O and 4P). In
contrast, no signiﬁcant difference in the ventricular-end
diastolic diameter was observed. These ﬁndings were as-
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Figure 2. Clinical features of the mutation carrier. A, Twelve-
lead resting ECG (50 mm/s). Note the T-wave inversions in the
leads V1–V6 and the epsilon wave (arrow) in V1. B, ECG (25 mm/
s) of a ventricular tachycardia with left bundle branch block mor-
phology. C, Image of an angiogram showing an enlarged right
ventricle in 30 right-anterior oblique, with evidence of diastolic
bulging (arrowheads) at the right ventricle inﬂow tract and diffuse
inferior hypokinesia (arrows).
Table 2. Oligonucleotide Primer Sequences
Primer
Primer Sequence
(5′r3′)
c607F CGTGAGCAGTATGAATCTTTTGAG
c800R GCACACACTTGTCCCACAGTAGTG
c1073R GTACGAGTAAATGTTGGCAAGTG
c631F ATAATTGCCTTTGCAACAACTCCAG
cMutF CAGTATGAATCTTTTGAGATGGG
sociated with minor focal CNS necrosis (correlating with
the brain expression domain of zebraﬁsh dsc2). Electron
microscopy (EM) revealed that the normal desmosomal
extracellular electron-dense midline failed to form in the
myocardial tissue of the ventricle in morphant embryos
at 48 hpf but was present in control embryos (ﬁg. 4I–4K).
Rescue of the dsc2 morphant cardiac phenotypes was
possible with coinjection of wild-type human DSC2mRNA
but not with mRNA encoding the mutant human DSC2
(ﬁg. 5A–5C). Using a dose of dsc2 morpholino resulting
in a cardiac phenotype (bradycardia and edema) in 48.4%
of morphant embryos, we observed a substantial reduc-
tion in the proportion (7.8%) with cardiac dysfunction in
embryos injected with morpholino and wild-type DSC2
mRNA but no signiﬁcant reduction in the proportion
(26.4%) of embryos injected withmorpholino andmutant
DSC2 mRNA (ﬁg. 5C). Taken together, these ﬁndings sug-
gest that the dose of DSC2 is critical for normal cardiac
function and that the c.631-2ArG mutation encodes an
mRNA incapable of rescuing the in vivo effects of gene-
dose reduction.
DSC2—together with other desmosomal cadherins, ar-
madillo proteins, and plakins—form cell-adhesion com-
plexes that provide mechanical strength in tissues by an-
choring intermediate ﬁlaments. It has been suggested that
DSCs and DSGs, in addition to their cell-adhesion func-
tion, act as molecular sensors regulating cellular behavior
and transducing cellular signals.17–19 The dominant DSC2
mutation (c.631-2ArG) described here predicts a trunca-
ted DSC2 protein lacking the highly conserved CAR se-
quence located in the ﬁrst EC1 domain, which is present
in all classic and desmosomal cadherins. Studies of classic
cadherins suggest that the CAR sequence forms part of an
adhesive interface between cadherin molecules on op-
posite cell surfaces and led to the postulation of an “ad-
hesion zipper” model.24 Dominant negative mutants (de-
letion of EC1–EC4) of different desmosomal cadherins
transfected into cultured keratinocytes with adenoviral
vector disrupt cell-cell adhesion.25,26 The truncated protein
encoded by the mutant allele in this case may have a
dominant negative effect disrupting cell-cell adhesion,
but the markedly decreased levels of mRNA observed with
the mutant DSC2 allele suggest that nonsense-mediated
mRNA decay and consequent haploinsufﬁciency likely
contribute to the disease mechanism.
Knockdown of dsc2 in zebraﬁsh results in dose-depen-
dent bradycardia, impaired contractility, and cardiac
edema, associated with consistent loss of the desmosomal
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Figure 3. Expression analysis of the mutant DSC2. A, Allele-spe-
ciﬁc quantitative real-time PCR of DSC2 wild-type (WT) and mutant
(MUT) mRNA of cardiac tissue derived from patient (P) and control
(C) samples. Note the reduced expression (3%) of the mutant allele
in cardiac tissue in the patient. B, Western-blot analysis of a right
ventricular biopsy sample obtained from the patient with the DSC2
mutation c.631-2ArG. Note that the amount of DSC2 in the patient
is reduced when compared with control myocardium. Blots were
probed with antibodies for DSC2 (Progen, 1:10,000) and a-tubulin
(Sigma-Aldrich, 1:5,000) as loading control.
extracellular electron-dense midlines. This structure con-
taining the ﬁve extracellular subdomains of DSC2 is im-
portant for homophilic dimerization in cis and trans ori-
entation as well as for stable cell-cell contacts. Impor-
tantly, we were able to rescue the dsc2 knockdown cardiac
phenotype with wild-type human DSC2 mRNA but not
with mutant (c.631-2ArG) mRNA. These studies indicate
that physiologic levels of DSC2 are crucial for early cardiac
morphogenesis, desmosome formation, and normal car-
diac function, as well as independently conﬁrming the in
vivo loss of function of the truncated mutant protein.
Mutations in other desmosomal cadherins have been
described in different human skin diseases. An N-terminal
deletion in DSG1 causes autosomal dominant striate pal-
moplantar keratoderma (PPKS1 [MIM 148700]),26 and
DSG4 mutations result in defective hair follicle differen-
tiation (LAH [MIM 607903]).27 DSC2 and DSG2 are ex-
pressed ubiquitously in desmosomal-containing tissues,21
butDSG1 and -3 andDSC1 and -3 are restricted to stratiﬁed
epithelia.18 Although DSC2 is expressed in skin epithelium
as well as in many other tissues, no additional phenotypic
features could be detected in the affected patient. It is
possible that absence of cutaneous abnormalities in our
patient with a DSC2 mutation could be due to compen-
sation by other desmosomal cadherins in skin but not in
cardiac tissue. DSC1 and DSC3, which are also mainly ex-
pressed in the basal layer of the epidermis, are excellent
candidates to compensate for DSC2 function. This hypo-
thesis is supported by in vitro studies, which have dem-
onstrated adhesive interactions between different iso-
forms of cadherins that occur in the same desmosome.28–30
Recently, it was reported that mutations in DSG2 ac-
count for a signiﬁcant proportion of ARVC in Italian and
U.S. populations,14,22 but we were unable to conﬁrm this
result in our cohort of 88 patients with ARVC. Possible
reasons for such a variable prevalence of DSG2 mutations
in cohorts with ARVC include the geographic or ethnic
origins of the populations, selection biases, and the rela-
tively small sizes of the original cohorts studied.
Whereas the involvement of multiple desmosomal pro-
tein genes has led to speculation regarding the sensitivity
of myocardium to mechanical disruption, the pathogenic
mechanisms leading to ARVC in humans are not clear.
Mice null for various junctional protein genes (Dsp, Jup,
Pkp2, and Cdh2) expressed in cardiac tissue exhibit em-
bryonic lethality, with multiple developmental abnor-
malities, including severe cardiovascular defects.31–34 Re-
cently, Garcia-Gras et al.35 reported that heterozygous
cardiac-restricted deletion of Dsp in mice partially reca-
pitulates the phenotype of human ARVC. These research-
ers also suggested a novel molecular mechanism for adi-
pocytic and ﬁbrous replacement of myocytes in the
pathogenesis of ARVC, controlled by the canonical Wnt/
b-catenin signaling pathway.35 Further in vivo and in vitro
studies of DSC2 and other desmosomal molecules in-
volved in the disease process will provide new insights
into the molecular mechanisms of ARVC.
In conclusion, we describe the ﬁrst evidence, to our
knowledge, of disease-causing mutation in the human
DSC2 gene: a heterozygous mutation (c.631-2ArG) re-
sulting in ARVC. Expression analyses in the affected pa-
tient suggest that DSC2 gene dose may contribute to the
disease pathogenesis. This is further supported by evi-
dence that graded knockdown of dsc2 in zebraﬁsh em-
bryos profoundly perturbs myocardial desmosome struc-
ture and contractile function.
Figure 4. Zebraﬁsh dsc2 expression and knockdown. A–D, Zebraﬁsh dsc2 expression. Whole-mount in situ hybridizations with use of
full-length sense (A) and antisense (B) zebraﬁsh dsc2 riboprobe show weak staining in the heart and brain at 48 hpf with the antisense
probe, whereas the sense control riboprobe does not reveal any staining. Scale bars indicate 100 mM. Higher magniﬁcation image of
the heart (C) and longitudinal section through the ventricle (D) of whole-mount in situ stained embryos conﬁrm cardiac expression.
Scale bars indicate 25 mM. a p Atrium; v p ventricle. E–P, Knockdown of dsc2 in zebraﬁsh. E, Phenotype at 48 hpf of an embryo
injected with mismatch control oligo compared with a morphant (injected with 25 ng of morpholino dsc2-1) embryo at the same stage
(F). Scale bars indicate 100 mM. High-resolution pictures of the heart of morphant embryo (H) compared with control-injected embryo
(G). Scale bars indicate 25 mM. Transmission EM of cardiac desmosomes from a control embryo (I) and a morphant embryo (J) at 48
hpf. Scale bars indicate 50 nm. K, Percentage of desmosomes with midline in control (C) and morphant (MO) embryos. L, Heart rate
measured at room temperature in morphant embryos compared with control injected embryos ( ). M, RT-PCR of zebraﬁsh dsc2, toP ! .05
determine morpholino efﬁciency. N, Fractional shortening of the ventricular chamber of control and morphant ﬁsh at 48 hpf. Diastolic
(O) and systolic (P) short-axis diameter measured in controls and morphant embryos ( ).P ! .05
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Figure 5. Rescue of dsc2 morphants (MO). A, Wild-type phe-
notype. B, Morphant phenotype. C, Rescue of dsc2 morphant phe-
notype (blackened bars) is seen with wild-type (WT) (unblackened
bars) but not with mutant (MUT) DSC2 mRNA. Results are based
on data from three different experiments with 25 ng of morpholino
and 1 pg of the respective capped mRNAs.
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